Reuters 
(2/1, Pittman) reports that, according to research published in the
American Journal of Gastroenterology, most diabetes drugs may be linked
to an increased risk of pancreatic cancer.
(2/1, Pittman) reports that, according to research published in the
American Journal of Gastroenterology, most diabetes drugs may be linked
to an increased risk of pancreatic cancer.
HealthDay
(2/1, Mozes) reports, however, that "short-term use of metformin or
sulfonylureas and/or insulin had no appreciable impact on pancreatic
cancer risk." But, the researchers found that "long-term use of each of
these medications did appear to have a sizeable impact on pancreatic
cancer risk among diabetics." Although "female patients saw their risk
go down with metformin treatment and up with sulfonylureas, male
patients saw their risk go up with insulin."
(2/1, Mozes) reports, however, that "short-term use of metformin or
sulfonylureas and/or insulin had no appreciable impact on pancreatic
cancer risk." But, the researchers found that "long-term use of each of
these medications did appear to have a sizeable impact on pancreatic
cancer risk among diabetics." Although "female patients saw their risk
go down with metformin treatment and up with sulfonylureas, male
patients saw their risk go up with insulin."
Reuters
(2/1, Pittman) reports that, according to research published in the
American Journal of Gastroenterology, most diabetes drugs may be linked
to an increased risk of pancreatic cancer.
Medscape
(2/1, Franklin) reports, "Drawing on data from the United Kingdom–based
General Practice Research Database, the investigators identified a
cohort of 2763 patients (1276 men and 1487 women) who had a first-time
diagnosis of pancreatic cancer between 1995 and 2009, along with 16,578
matched control patients. Of those, 307 (11.1%) of the patients in the
case group had diabetes, as did 1347 (8.1%) in the matched control
patients." In order "to assess the effect of antidiabetic drugs on
pancreatic cancer risk, the investigators stratified patients according
to the duration of use (short-, medium-, or long-term), based on the
number of prescriptions filled for metformin, sulfonylureas, and/or
insulin during the study period."
HealthDay
(2/1, Mozes) reports, "Short-term use of metformin or sulfonylureas
and/or insulin had no appreciable impact on pancreatic cancer risk."
But, the researchers found that "long-term use of each of these
medications did appear to have a sizeable impact on pancreatic cancer
risk among diabetics." Although "female patients saw their risk go down
with metformin treatment and up with sulfonylureas, male patients saw
their
risk go up with insulin."
No comments:
Post a Comment